Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: harpoontx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2024 | $23.00 | Outperform | Oppenheimer |
| 11/20/2023 | Outperform | TD Cowen | |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 11/11/2021 | $25.00 → $19.00 | Outperform | SVB Leerink |
| 9/28/2021 | $16.00 | Neutral → Buy | Citigroup |
| 8/6/2021 | $29.00 → $25.00 | Outperform | SVB Leerink |